BioMarin Pharmaceuticals Inc (BMRN) — 分析摘要
BioMarin Pharmaceuticals Inc（BMRN）的市值为11.44十亿美元，最近一年的营收同比增长了+12.9%。净利润率为10.8%。当前市盈率为42.6倍。
核心要点
- 营收同比变化+12.9%
- 净利润率10.8%
- 市盈率42.6倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，BMRN的营收增长为+12.9%，市盈率为42.6倍。
BioMarin Pharmaceuticals Inc (BMRN)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
3,221
总部
NOVATO, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。